Skip to main content
Erschienen in: Current Heart Failure Reports 6/2017

26.10.2017 | Prevention of Heart Failure (M Sutton, Section Editor)

Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment

verfasst von: Vincenzo B. Polsinelli, Arjun Sinha, Sanjiv J. Shah

Erschienen in: Current Heart Failure Reports | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Visceral venous congestion of the gut may play a key role in the pathogenesis of right-sided heart failure (HF) and cardiorenal syndromes. Here, we review the role of right ventricular (RV) dysfunction, visceral congestion, splanchnic hemodynamics, and the intestinal microenvironment in the setting of right-sided HF. We review recent literature on this topic, outline possible mechanisms of disease pathogenesis, and discuss potential therapeutics.

Recent Findings

There are several mechanisms linking RV–gut interactions via visceral venous congestion which could result in (1) hypoxia and acidosis in enterocytes, which may lead to enhanced sodium–hydrogen exchanger 3 (NHE3) expression with increased sodium and fluid retention; (2) decreased luminal pH in the intestines, which could lead to alteration of the gut microbiome which could increase gut permeability and inflammation; (3) alteration of renal hemodynamics with triggering of the cardiorenal syndrome; and (4) altered phosphate metabolism resulting in increased pulmonary artery stiffening, thereby increasing RV afterload. A wide variety of therapeutic interventions that act on the RV, pulmonary vasculature, intestinal microenvironment, and the kidney could alter these pathways and should be tested in patients with right-sided HF.

Summary

The RV–gut axis is an important aspect of HF pathogenesis that deserves more attention. Modulation of the pathways interconnecting the right heart, visceral congestion, and the intestinal microenvironment could be a novel avenue of intervention for right-sided HF.
Literatur
1.
Zurück zum Zitat Spinarova L, Meluzin J, Toman J, Hude P, Krejci J, Vitovec J. Right ventricular dysfunction in chronic heart failure patients. Eur J Heart Fail. 2005;7(4):485–9.CrossRefPubMed Spinarova L, Meluzin J, Toman J, Hude P, Krejci J, Vitovec J. Right ventricular dysfunction in chronic heart failure patients. Eur J Heart Fail. 2005;7(4):485–9.CrossRefPubMed
2.
Zurück zum Zitat Puwanant S, Priester TC, Mookadam F, Bruce CJ, Redfield MM, Chandrasekaran K. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr. 2009;10(6):733–7.CrossRefPubMed Puwanant S, Priester TC, Mookadam F, Bruce CJ, Redfield MM, Chandrasekaran K. Right ventricular function in patients with preserved and reduced ejection fraction heart failure. Eur J Echocardiogr. 2009;10(6):733–7.CrossRefPubMed
3.
Zurück zum Zitat Gorter TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, Lam CS, Geelhoed B, et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2016;18:1472–87.CrossRefPubMed Gorter TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, Lam CS, Geelhoed B, et al. Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail. 2016;18:1472–87.CrossRefPubMed
5.
Zurück zum Zitat Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, Fox J, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288–99.CrossRefPubMed Burke MA, Katz DH, Beussink L, Selvaraj S, Gupta DK, Fox J, et al. Prognostic importance of pathophysiologic markers in patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014;7(2):288–99.CrossRefPubMed
6.
Zurück zum Zitat Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345(8):574–81.CrossRefPubMed Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345(8):574–81.CrossRefPubMed
7.
Zurück zum Zitat Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.CrossRefPubMedPubMedCentral Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–96.CrossRefPubMedPubMedCentral Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53(7):589–96.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Valentova M, von Haehling S, Krause C, Ebner N, Steinbeck L, Cramer L, et al. Cardiac cachexia is associated with right ventricular failure and liver dysfunction. Int J Cardiol. 2013;169(3):219–24.CrossRefPubMed Valentova M, von Haehling S, Krause C, Ebner N, Steinbeck L, Cramer L, et al. Cardiac cachexia is associated with right ventricular failure and liver dysfunction. Int J Cardiol. 2013;169(3):219–24.CrossRefPubMed
10.
Zurück zum Zitat • Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J. 2016;37(21):1684–91. This is a recent article that found that visceral (intestinal) congestion is the strongest factor associated with cardiac cachexia in heart failure patients. CrossRefPubMed • Valentova M, von Haehling S, Bauditz J, Doehner W, Ebner N, Bekfani T, et al. Intestinal congestion and right ventricular dysfunction: a link with appetite loss, inflammation, and cachexia in chronic heart failure. Eur Heart J. 2016;37(21):1684–91. This is a recent article that found that visceral (intestinal) congestion is the strongest factor associated with cardiac cachexia in heart failure patients. CrossRefPubMed
11.
Zurück zum Zitat Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561–9.CrossRefPubMed Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561–9.CrossRefPubMed
12.
Zurück zum Zitat Valentova M, von Haehling S, Anker SD, Sandek A. Cardiac hepatopathy versus end-stage liver disease: two different entities. J Am Coll Cardiol. 2014;63(17):1809–10.CrossRefPubMed Valentova M, von Haehling S, Anker SD, Sandek A. Cardiac hepatopathy versus end-stage liver disease: two different entities. J Am Coll Cardiol. 2014;63(17):1809–10.CrossRefPubMed
13.
Zurück zum Zitat Charalambous BM, Stephens RC, Feavers IM, Montgomery HE. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock. 2007;28(1):15–23.CrossRefPubMed Charalambous BM, Stephens RC, Feavers IM, Montgomery HE. Role of bacterial endotoxin in chronic heart failure: the gut of the matter. Shock. 2007;28(1):15–23.CrossRefPubMed
14.
Zurück zum Zitat Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013;61(22):2253–61.CrossRefPubMedPubMedCentral Kim MS, Kato TS, Farr M, Wu C, Givens RC, Collado E, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol. 2013;61(22):2253–61.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947. Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947.
16.
Zurück zum Zitat Koutsos A, Tuohy KM, Lovegrove JA. Apples and cardiovascular health—is the gut microbiota a core consideration? Nutrients. 2015;7(6):3959–98.CrossRefPubMedPubMedCentral Koutsos A, Tuohy KM, Lovegrove JA. Apples and cardiovascular health—is the gut microbiota a core consideration? Nutrients. 2015;7(6):3959–98.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Li D, Kirsop J, Tang WH. Listening to our gut: contribution of gut microbiota and cardiovascular risk in diabetes pathogenesis. Curr Diab Rep. 2015;15(9):63.CrossRefPubMedPubMedCentral Li D, Kirsop J, Tang WH. Listening to our gut: contribution of gut microbiota and cardiovascular risk in diabetes pathogenesis. Curr Diab Rep. 2015;15(9):63.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol. 2014;9(3):399–410.CrossRefPubMed Mafra D, Lobo JC, Barros AF, Koppe L, Vaziri ND, Fouque D. Role of altered intestinal microbiota in systemic inflammation and cardiovascular disease in chronic kidney disease. Future Microbiol. 2014;9(3):399–410.CrossRefPubMed
19.
Zurück zum Zitat Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817–44.CrossRefPubMed Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31(6):817–44.CrossRefPubMed
20.
Zurück zum Zitat Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015;17(12):120.CrossRefPubMed Miele L, Giorgio V, Alberelli MA, De Candia E, Gasbarrini A, Grieco A. Impact of gut microbiota on obesity, diabetes, and cardiovascular disease risk. Curr Cardiol Rep. 2015;17(12):120.CrossRefPubMed
21.
Zurück zum Zitat Sanduzzi Zamparelli M, Compare D, Coccoli P, Rocco A, Nardone OM, Marrone G, et al. The metabolic role of gut microbiota in the development of nonalcoholic fatty liver disease and cardiovascular disease. Int J Mol Sci. 2016;17(8):E1225. Sanduzzi Zamparelli M, Compare D, Coccoli P, Rocco A, Nardone OM, Marrone G, et al. The metabolic role of gut microbiota in the development of nonalcoholic fatty liver disease and cardiovascular disease. Int J Mol Sci. 2016;17(8):E1225.
22.
Zurück zum Zitat Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep. 2014;16(11):540.CrossRefPubMedPubMedCentral Serino M, Blasco-Baque V, Nicolas S, Burcelin R. Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep. 2014;16(11):540.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183–96.CrossRefPubMed Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017;120(7):1183–96.CrossRefPubMed
25.
Zurück zum Zitat Tuohy KM, Fava F, Viola R. The way to a man’s heart is through his gut microbiota’—dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc. 2014;73(2):172–85.CrossRefPubMed Tuohy KM, Fava F, Viola R. The way to a man’s heart is through his gut microbiota’—dietary pro- and prebiotics for the management of cardiovascular risk. Proc Nutr Soc. 2014;73(2):172–85.CrossRefPubMed
26.
Zurück zum Zitat Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis. 2013;231(2):456–61.CrossRefPubMed Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis. 2013;231(2):456–61.CrossRefPubMed
27.
Zurück zum Zitat Yamashita T, Kasahara K, Emoto T, Matsumoto T, Mizoguchi T, Kitano N, et al. Intestinal immunity and gut microbiota as therapeutic targets for preventing atherosclerotic cardiovascular diseases. Circ J. 2015;79(9):1882–90.CrossRefPubMed Yamashita T, Kasahara K, Emoto T, Matsumoto T, Mizoguchi T, Kitano N, et al. Intestinal immunity and gut microbiota as therapeutic targets for preventing atherosclerotic cardiovascular diseases. Circ J. 2015;79(9):1882–90.CrossRefPubMed
28.
Zurück zum Zitat Bookstein C, DePaoli AM, Xie Y, Niu P, Musch MW, Rao MC, et al. Na+/H+ exchangers, NHE-1 and NHE-3, of rat intestine. Expression and localization. J Clin Invest. 1994;93(1):106–13.CrossRefPubMedPubMedCentral Bookstein C, DePaoli AM, Xie Y, Niu P, Musch MW, Rao MC, et al. Na+/H+ exchangers, NHE-1 and NHE-3, of rat intestine. Expression and localization. J Clin Invest. 1994;93(1):106–13.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Kiela PR, Guner YS, Xu H, Collins JF, Ghishan FK. Age- and tissue-specific induction of NHE3 by glucocorticoids in the rat small intestine. Am J Physiol Cell Physiol. 2000;278(4):C629–37.PubMed Kiela PR, Guner YS, Xu H, Collins JF, Ghishan FK. Age- and tissue-specific induction of NHE3 by glucocorticoids in the rat small intestine. Am J Physiol Cell Physiol. 2000;278(4):C629–37.PubMed
30.
Zurück zum Zitat Broere N, Chen M, Cinar A, Singh AK, Hillesheim J, Riederer B, et al. Defective jejunal and colonic salt absorption and altered Na(+)/H (+) exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor protein-deficient mice. Pflugers Arch. 2009;457(5):1079–91.CrossRefPubMed Broere N, Chen M, Cinar A, Singh AK, Hillesheim J, Riederer B, et al. Defective jejunal and colonic salt absorption and altered Na(+)/H (+) exchanger 3 (NHE3) activity in NHE regulatory factor 1 (NHERF1) adaptor protein-deficient mice. Pflugers Arch. 2009;457(5):1079–91.CrossRefPubMed
31.
Zurück zum Zitat Gawenis LR, Stien X, Shull GE, Schultheis PJ, Woo AL, Walker NM, et al. Intestinal NaCl transport in NHE2 and NHE3 knockout mice. Am J Physiol Gastrointest Liver Physiol. 2002;282(5):G776–84.CrossRefPubMed Gawenis LR, Stien X, Shull GE, Schultheis PJ, Woo AL, Walker NM, et al. Intestinal NaCl transport in NHE2 and NHE3 knockout mice. Am J Physiol Gastrointest Liver Physiol. 2002;282(5):G776–84.CrossRefPubMed
32.
Zurück zum Zitat Musch MW, Lucioni A, Chang EB. Aldosterone regulation of intestinal Na absorption involves SGK-mediated changes in NHE3 and Na+ pump activity. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G909–19.CrossRefPubMedPubMedCentral Musch MW, Lucioni A, Chang EB. Aldosterone regulation of intestinal Na absorption involves SGK-mediated changes in NHE3 and Na+ pump activity. Am J Physiol Gastrointest Liver Physiol. 2008;295(5):G909–19.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Lucioni A, Womack C, Musch MW, Rocha FL, Bookstein C, Chang EB. Metabolic acidosis in rats increases intestinal NHE2 and NHE3 expression and function. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G51–6.CrossRefPubMed Lucioni A, Womack C, Musch MW, Rocha FL, Bookstein C, Chang EB. Metabolic acidosis in rats increases intestinal NHE2 and NHE3 expression and function. Am J Physiol Gastrointest Liver Physiol. 2002;283(1):G51–6.CrossRefPubMed
34.
Zurück zum Zitat Giral H, Cranston D, Lanzano L, Caldas Y, Sutherland E, Rachelson J, et al. NHE3 regulatory factor 1 (NHERF1) modulates intestinal sodium-dependent phosphate transporter (NaPi-2b) expression in apical microvilli. J Biol Chem. 2012;287(42):35047–56.CrossRefPubMedPubMedCentral Giral H, Cranston D, Lanzano L, Caldas Y, Sutherland E, Rachelson J, et al. NHE3 regulatory factor 1 (NHERF1) modulates intestinal sodium-dependent phosphate transporter (NaPi-2b) expression in apical microvilli. J Biol Chem. 2012;287(42):35047–56.CrossRefPubMedPubMedCentral
35.
36.
Zurück zum Zitat Pluznick JA. Novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014;5(2):202–7.CrossRefPubMed Pluznick JA. Novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014;5(2):202–7.CrossRefPubMed
37.
Zurück zum Zitat Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110(11):4410–5.CrossRefPubMedPubMedCentral Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci U S A. 2013;110(11):4410–5.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G-protein coupled receptor 41. Physiol Genomics. 2016;48(11):826-834. Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G-protein coupled receptor 41. Physiol Genomics. 2016;48(11):826-834.
39.
Zurück zum Zitat Organ CL, Otsuka H, Bhushan S, Wang Z, Bradley J, Trivedi R, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016;9(1):e002314.CrossRefPubMed Organ CL, Otsuka H, Bhushan S, Wang Z, Bradley J, Trivedi R, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016;9(1):e002314.CrossRefPubMed
40.
Zurück zum Zitat Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Tang WH, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc 2016;5(6):e002816. Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Tang WH, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc 2016;5(6):e002816.
41.
Zurück zum Zitat Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol. 2016;67(22):2620–8.CrossRefPubMedPubMedCentral Senthong V, Li XS, Hudec T, Coughlin J, Wu Y, Levison B, et al. Plasma trimethylamine N-oxide, a gut microbe-generated phosphatidylcholine metabolite, is associated with atherosclerotic burden. J Am Coll Cardiol. 2016;67(22):2620–8.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–14.CrossRefPubMed Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–14.CrossRefPubMed
43.
Zurück zum Zitat Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation. 2017;135(10):964–77.CrossRefPubMed Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice. Circulation. 2017;135(10):964–77.CrossRefPubMed
44.
Zurück zum Zitat Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.CrossRefPubMed Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.CrossRefPubMed
45.
Zurück zum Zitat Tang WH, Wang Z, Li XS, Fan Y, Li DS, Wu Y, et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem. 2017;63(1):297–306.CrossRefPubMed Tang WH, Wang Z, Li XS, Fan Y, Li DS, Wu Y, et al. Increased trimethylamine N-oxide portends high mortality risk independent of glycemic control in patients with type 2 diabetes mellitus. Clin Chem. 2017;63(1):297–306.CrossRefPubMed
46.
Zurück zum Zitat •• Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24. This paper describes the mechanistic link between the gut-derived microbial metabolite TMAO, enhanced platelet reactivity, and thrombosis risk. CrossRefPubMedPubMedCentral •• Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24. This paper describes the mechanistic link between the gut-derived microbial metabolite TMAO, enhanced platelet reactivity, and thrombosis risk. CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135(17):1671–3.CrossRefPubMed Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe-generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects. Circulation. 2017;135(17):1671–3.CrossRefPubMed
48.
Zurück zum Zitat Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29(9):992–9.CrossRefPubMed Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther. 2009;29(9):992–9.CrossRefPubMed
49.
Zurück zum Zitat Dong T, Aronsohn A, Gautham Reddy K, Te HS. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 2016. Dong T, Aronsohn A, Gautham Reddy K, Te HS. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig Dis Sci. 2016.
50.
Zurück zum Zitat Ponziani FR, Gerardi V, Pecere S, D'Aversa F, Lopetuso L, Zocco MA, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015;21(43):12322–33.CrossRefPubMedPubMedCentral Ponziani FR, Gerardi V, Pecere S, D'Aversa F, Lopetuso L, Zocco MA, et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol. 2015;21(43):12322–33.CrossRefPubMedPubMedCentral
51.
Zurück zum Zitat Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012;157(1):80–5.CrossRefPubMed Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, et al. Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol. 2012;157(1):80–5.CrossRefPubMed
52.
Zurück zum Zitat Sandek A, Anker SD, von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab. 2009;10(1):22–8.CrossRefPubMed Sandek A, Anker SD, von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab. 2009;10(1):22–8.CrossRefPubMed
53.
Zurück zum Zitat Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11(5):632–9.CrossRefPubMed Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11(5):632–9.CrossRefPubMed
54.
Zurück zum Zitat Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34(10):742–9.CrossRefPubMed Nikolaou M, Parissis J, Yilmaz MB, Seronde MF, Kivikko M, Laribi S, et al. Liver function abnormalities, clinical profile, and outcome in acute decompensated heart failure. Eur Heart J. 2013;34(10):742–9.CrossRefPubMed
55.
Zurück zum Zitat Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail. 2016;4(3):220–7.CrossRefPubMed Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, et al. Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail. 2016;4(3):220–7.CrossRefPubMed
56.
Zurück zum Zitat Poelzl G, Ess M, Von der Heidt A, Rudnicki M, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance. Eur J Intern Med. 2013;24(2):177–82.CrossRefPubMed Poelzl G, Ess M, Von der Heidt A, Rudnicki M, Frick M, Ulmer H. Concomitant renal and hepatic dysfunctions in chronic heart failure: clinical implications and prognostic significance. Eur J Intern Med. 2013;24(2):177–82.CrossRefPubMed
57.
Zurück zum Zitat Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014;64(11):1092–102.CrossRefPubMed Sandek A, Swidsinski A, Schroedl W, Watson A, Valentova M, Herrmann R, et al. Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia. J Am Coll Cardiol. 2014;64(11):1092–102.CrossRefPubMed
58.
Zurück zum Zitat Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51(3):300–6.CrossRefPubMed Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51(3):300–6.CrossRefPubMed
59.
Zurück zum Zitat Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail. 2014;20(5):319–26.CrossRefPubMed Kalogeropoulos AP, Tang WH, Hsu A, Felker GM, Hernandez AF, Troughton RW, et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail. 2014;20(5):319–26.CrossRefPubMed
60.
Zurück zum Zitat Cetin S, Dunklebarger J, Li J, Boyle P, Ergun O, Qureshi F, et al. Endotoxin differentially modulates the basolateral and apical sodium/proton exchangers (NHE) in enterocytes. Surgery. 2004;136(2):375–83.CrossRefPubMed Cetin S, Dunklebarger J, Li J, Boyle P, Ergun O, Qureshi F, et al. Endotoxin differentially modulates the basolateral and apical sodium/proton exchangers (NHE) in enterocytes. Surgery. 2004;136(2):375–83.CrossRefPubMed
61.
Zurück zum Zitat Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–54.CrossRefPubMed Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL. Left ventricular heart failure and pulmonary hypertension. Eur Heart J. 2016;37(12):942–54.CrossRefPubMed
62.
Zurück zum Zitat Dixon DD, Trivedi A, Shah SJ. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Fail Rev. 2016;21(3):285–97.CrossRefPubMed Dixon DD, Trivedi A, Shah SJ. Combined post- and pre-capillary pulmonary hypertension in heart failure with preserved ejection fraction. Heart Fail Rev. 2016;21(3):285–97.CrossRefPubMed
63.
Zurück zum Zitat Thenappan T, Prins KW, Cogswell R, Shah SJ. Pulmonary hypertension secondary to heart failure with preserved ejection fraction. Can J Cardiol. 2015;31(4):430–9.CrossRefPubMed Thenappan T, Prins KW, Cogswell R, Shah SJ. Pulmonary hypertension secondary to heart failure with preserved ejection fraction. Can J Cardiol. 2015;31(4):430–9.CrossRefPubMed
64.
Zurück zum Zitat Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18(1):103–12.CrossRefPubMed Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18(1):103–12.CrossRefPubMed
65.
Zurück zum Zitat Westerhof N, Westerhof BE. A review of methods to determine the functional arterial parameters stiffness and resistance. J Hypertens. 2013;31(9):1769–75.CrossRefPubMed Westerhof N, Westerhof BE. A review of methods to determine the functional arterial parameters stiffness and resistance. J Hypertens. 2013;31(9):1769–75.CrossRefPubMed
66.
67.
68.
Zurück zum Zitat Akmal M, Barndt RR, Ansari AN, Mohler JG, Massry SG, Excess PTH. In CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int. 1995;47(1):158–63.CrossRefPubMed Akmal M, Barndt RR, Ansari AN, Mohler JG, Massry SG, Excess PTH. In CRF induces pulmonary calcification, pulmonary hypertension and right ventricular hypertrophy. Kidney Int. 1995;47(1):158–63.CrossRefPubMed
69.
Zurück zum Zitat Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933–42.CrossRefPubMed Block GA, Rosenbaum DP, Leonsson-Zachrisson M, Astrand M, Johansson S, Knutsson M, et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J Am Soc Nephrol. 2017;28(6):1933–42.CrossRefPubMed
70.
Zurück zum Zitat Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs. 2016;25(1):117–27.CrossRefPubMed Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure. Expert Opin Investig Drugs. 2016;25(1):117–27.CrossRefPubMed
71.
Zurück zum Zitat Khan SS, Cuttica MJ, Beussink-Nelson L, Kozyleva A, Sanchez C, Mkrdichian H, et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ. 2015;5(3):547–56.CrossRefPubMedPubMedCentral Khan SS, Cuttica MJ, Beussink-Nelson L, Kozyleva A, Sanchez C, Mkrdichian H, et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ. 2015;5(3):547–56.CrossRefPubMedPubMedCentral
72.
Zurück zum Zitat Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J. 2009;157(6):1035–41.CrossRefPubMed Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. Am Heart J. 2009;157(6):1035–41.CrossRefPubMed
73.
Zurück zum Zitat Craig ML. Management of right ventricular failure in the era of ventricular assist device therapy. Curr Heart Fail Rep. 2011;8(1):65–71.CrossRefPubMed Craig ML. Management of right ventricular failure in the era of ventricular assist device therapy. Curr Heart Fail Rep. 2011;8(1):65–71.CrossRefPubMed
74.
Zurück zum Zitat Kapur NK, Bader YH. Percutaneous circulatory assist devices for right ventricular failure. Interv. Cardiol Clin. 2013;2(3):445–56. Kapur NK, Bader YH. Percutaneous circulatory assist devices for right ventricular failure. Interv. Cardiol Clin. 2013;2(3):445–56.
75.
Zurück zum Zitat Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136–44.CrossRefPubMed Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol. 2007;50(22):2136–44.CrossRefPubMed
76.
Zurück zum Zitat Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8–17.CrossRefPubMed Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail. 2011;4(1):8–17.CrossRefPubMed
77.
Zurück zum Zitat Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–11.CrossRefPubMed Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–11.CrossRefPubMed
78.
Zurück zum Zitat Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson MA. Phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–16.CrossRefPubMed Johansson S, Rosenbaum DP, Knutsson M, Leonsson-Zachrisson MA. Phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers. Clin Exp Nephrol. 2017;21(3):407–16.CrossRefPubMed
79.
Zurück zum Zitat • Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra36. Spencer et al. describe the protective beneficial effect of gut NHE3 inhibition on cardiorenal damage in rats. CrossRefPubMed • Spencer AG, Labonte ED, Rosenbaum DP, Plato CF, Carreras CW, Leadbetter MR, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6(227):227ra36. Spencer et al. describe the protective beneficial effect of gut NHE3 inhibition on cardiorenal damage in rats. CrossRefPubMed
80.
Zurück zum Zitat Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–9.CrossRefPubMed Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2(9):1025–9.CrossRefPubMed
81.
Zurück zum Zitat Turner JR, Black ED. NHE3-dependent cytoplasmic alkalinization is triggered by Na(+)-glucose cotransport in intestinal epithelia. Am J Physiol Cell Physiol. 2001;281(5):C1533–41.PubMed Turner JR, Black ED. NHE3-dependent cytoplasmic alkalinization is triggered by Na(+)-glucose cotransport in intestinal epithelia. Am J Physiol Cell Physiol. 2001;281(5):C1533–41.PubMed
82.
Zurück zum Zitat Ghosh P. The stress polarity pathway: AMPK ‘GIV’-es protection against metabolic insults. Aging (Albany NY). 2017;9(2):303–14. Ghosh P. The stress polarity pathway: AMPK ‘GIV’-es protection against metabolic insults. Aging (Albany NY). 2017;9(2):303–14.
83.
Zurück zum Zitat Shih CJ, YL W, Chao PW, Kuo SC, Yang CY, Li SY, et al. Association between use of oral anti-diabetic drugs and the risk of sepsis: a nested case-control study. Sci Rep. 2015;5:15260.CrossRefPubMedPubMedCentral Shih CJ, YL W, Chao PW, Kuo SC, Yang CY, Li SY, et al. Association between use of oral anti-diabetic drugs and the risk of sepsis: a nested case-control study. Sci Rep. 2015;5:15260.CrossRefPubMedPubMedCentral
Metadaten
Titel
Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment
verfasst von
Vincenzo B. Polsinelli
Arjun Sinha
Sanjiv J. Shah
Publikationsdatum
26.10.2017
Verlag
Springer US
Erschienen in
Current Heart Failure Reports / Ausgabe 6/2017
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-017-0370-8

Weitere Artikel der Ausgabe 6/2017

Current Heart Failure Reports 6/2017 Zur Ausgabe

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Glycosylated Chromogranin A: Potential Role in the Pathogenesis of Heart Failure

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

Genetics of Heart Failure (K Adams, Section Editor)

Pharmacogenomics of the Natriuretic Peptide System in Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (S Katz, Section Editor)

Skeletal muscle alterations in HFrEF vs. HFpEF

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.